Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

Authors
Category Primary study
JournalBLOOD
Year 2023
This article has no abstract
Epistemonikos ID: 88c1e5e2eff1b03fff43891d4bb784807321be4e
First added on: Apr 29, 2024